Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform', page-166

IMU barely has one foot on the bottom rung of the share price ladder. Whilst trading volumes suggest instos have upped their trading, many fund managers will be operating under mandates that preclude them from buying ‘penny stocks’. They will enter at higher prices. Also yet to join the fray are index managers, who will start to buy once we enter the ASX300 and will be considerably busier when we crack the 200 - possibly in 2021 in my view.

Our interim results massively derisked the stock and the lengthy list of applications for our two core products suggest that price ladder will be a very high extension job. Plenty of time to accumulate in my view ... barring big pharma turning up at the party, of course.


OOO